Lonza's full-year core EBITDA up 20.7% on vaccine demand

 FY core EBITDA 1.67 bln francs, in line with market view

* Guides for low to mid-teens forex adj sales growth

Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines.

Full-year core earnings before interest, tax, depreciation and amortization (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. That was broadly in line with an analyst consensus posted on its website.

The company, which is a key supplier of vaccine maker Moderna, is stepping up investments as it banks on long-term growth in the biopharmaceuticals sector well beyond the pandemic.

For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.

https://www.marketscreener.com/quote/stock/LONZA-GROUP-AG-2956013/news/Lonza-s-full-year-core-EBITDA-up-20-7-on-vaccine-demand-37642147/